remember the watershed announcement 2 years a

It was only 2 and a half years ago when PRR announced its world licence CVac as the ASX extract of this announcement reveals:

Prima BioMed:---- secure worldwide rights to the commercialisation of CVacTM

Tuesday 13 February 2007, Melbourne, Australia:

Key Points:
• Prima BioMed (“Prima”) has successfully negotiated a variation to the License and Development Agreement with Biomira Inc. (“Biomira”)

• Prima secures worldwide commercialisation rights for the Mucin-1 antigen for dendritic cell (DC) based therapies. Mucin-1 is the therapeutic target for Prima’s lead product candidate, CVacTM

• Prima now has the opportunity to pursue the development of CVacTM for worldwide registration and marketing. CVacTM’s first target indication is ovarian cancer

“Licensing Mucin-1 from Biomira has been a critical step in the development of our CVac™ technology. Prima is now in a stronger position to develop an internationally competitive immunotherapy-based oncology product. We now have certainty that we can access markets beyond just Australia and New Zealand.”

end of extract

I remember it well and was excited even then about the prospects of success for this product worldwide and all it would mean to the women suffering from ovarian cancer.

Many thanks to all the scientists at the Burnet Institute (was called the Austin Research Institute) in Melbourne where all the research associated with the CVac immunotherapy has been happening.

regards to all
Birdseye